Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.86 |
| ▸ | ERBB2 | P04626 | 14/20 | 0.86 |
| ▸ | ERBB4 | Q15303 | 9/20 | 0.86 |
| ▸ | JAK3 | P52333 | 2/20 | 0.86 |
| ▸ | GAK | O14976 | 1/20 | 0.86 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.86 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.86 |
| ▸ | LCK | P06239 | 1/20 | 0.86 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.86 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.86 |
| ▸ | SRC | P12931 | 1/20 | 0.86 |
| ▸ | DRD2 | P14416 | 1/20 | 0.86 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.86 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.86 |
| ▸ | MC3R | P41968 | 1/20 | 0.86 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.86 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.86 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.86 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30115344 | 1.00 | EGFR (0.86) | EGFRERBB2ERBB4JAK3GAK | |
| SCHEMBL30115307 | 0.96 | EGFR (0.84) | EGFRERBB2ERBB4JAK3GAK | |
| SCHEMBL30115319 | 0.94 | EGFR (0.86) | EGFRERBB2ERBB4JAK3GAK | |
| SCHEMBL30115358 | 0.94 | EGFR (0.78) | EGFRERBB2ERBB4JAK3GAK | |
| SCHEMBL30115322 | 0.93 | EGFR (0.78) | EGFRERBB2ERBB4JAK3GAK | |
| SCHEMBL30115346 | 0.93 | EGFR (0.77) | EGFRERBB2ERBB4JAK3GAK | |
| SCHEMBL33136 | 0.93 | EGFR (1.00) | EGFRERBB2ERBB4JAK3GAK | |
| SCHEMBL25098 | 0.93 | EGFR (1.00) | EGFRERBB2ERBB4JAK3GAK | |
| Dacomitinib Anhydrous SCHEMBL33147 | 0.93 | EGFR (1.00) | EGFRERBB2ERBB4JAK3GAK | |
| SCHEMBL30115337 | 0.93 | EGFR (1.00) | EGFRERBB2ERBB4JAK3GAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230001008-A1 | COMPOSITIONS AND METHODS FOR TARGETING CELLULAR MOLECULES | KUMQUAT BIOSCIENCES INC. | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230001008-A1 | COMPOSITIONS AND METHODS FOR TARGETING CELLULAR MOLECULES | CD2BP2, CD47, CD74 | EGFR 1892/4885ERBB2 2230/4885ERBB4 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.